美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

ABPRO HLDGS INC

3.89

-0.0300-0.77%

成交量：4,790.00

成交額：1.86萬

市值：1,056.63萬

市盈率：-0.33

高：3.96

開：3.91

低：3.87

收：3.92

52周最高：42.90

52周最低：3.78

股本：271.63萬

流通股本：100.62萬

量比：0.26

換手率：0.48%

股息：- -

股息率：- -

每股收益(TTM):-11.8955

每股收益(LYR):-22.3097

淨資產收益率：-125.45%

總資產收益率：-229.57%

市淨率：-0.65

市盈率(LYR):-0.17

資料載入中...

總覽公司新聞資訊公告

Abpro與Celltrion達成全球合作臨牀試驗預計2026年上半年啓動

Abpro與Celltrion宣佈其領先多特異性抗體抗癌候選藥物Abp-102/Ct-P72獲美國FDA IND許可

Abpro Holdings, Inc盤中異動早盤股價大跌5.69%

ABPRO HLDGS INC提交IND申請以啓動Abp-102/Ct-P72針對HER2陽性癌症的I期臨牀試驗

ABPRO控股公司提交有關可發行和轉售高達978萬股普通股的招股説明書 - SEC文件

ABPRO HLDGS INC：提交關於提供和轉售高達978萬股普通股的招股説明書 - SEC備案

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ABP/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABP\",,,,,undefined,":{"symbol":"ABP","market":"US","secType":"STK","nameCN":"ABPRO HLDGS INC","latestPrice":3.89,"timestamp":1768338000000,"preClose":3.92,"halted":0,"volume":4790,"delay":0,"floatShares":1006226,"shares":2716278,"eps":-11.895451,"marketStatus":"盤前交易","change":-0.03,"latestTime":"01-14 04:56:50 EST","open":3.91,"high":3.96,"low":3.87,"amount":18642.0815,"amplitude":0.022959,"askPrice":4.33,"askSize":100,"bidPrice":1.59,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-11.895451,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1768401000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1526011200000,"exchange":"NASDAQ","adjPreClose":3.96,"postHourTrading":{"tag":"盘后","latestPrice":3.89,"preClose":3.89,"latestTime":"16:10 EST","volume":3,"amount":11.88,"timestamp":1768338603506},"volumeRatio":0.2557558418174274},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ABP\",,,,,undefined,":{"symbol":"ABP","floatShares":1006226,"roa":"-229.57%","roe":"-125.45%","lyrEps":-22.309734,"volumeRatio":0.2557558418174274,"shares":2716278,"dividePrice":0,"high":3.96,"amplitude":0.022959,"preClose":3.92,"low":3.87,"week52Low":3.78,"pbRate":"-0.65","week52High":42.9,"institutionHeld":0,"latestPrice":3.89,"committee":0.333333,"eps":-11.895451,"divideRate":0,"volume":4790,"delay":0,"ttmEps":-11.895451,"open":3.91,"prevYearClose":4.23,"prevWeekClose":4.04,"prevMonthClose":4.23,"prevQuarterClose":4.23,"fiveDayClose":4.85,"twentyDayClose":5.87,"sixtyDayClose":5.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-14","symbol":"ABP","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1763096400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-11-03","symbol":"ABP","defaultRemindTime":1762180200000,"type":"split","dateTimestamp":1762146000000,"forFactor":30,"toFactor":1,"ratio":30}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ABP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ABP\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ABP","date":"2026-01-13","current":-0.327016,"percent":1,"low":-23.177979,"twenty":-4.195391,"median":-1.54141,"eighty":-1.156971,"high":-0.897565,"avg":-3.011243,"sd":3.617046,"marketCap":10647809},"quantilePoints":[{"date":"2024-11-22","current":-19.866839,"twenty":-22.778143,"median":-21.303749,"eighty":-20.955892,"marketCap":160663127},{"date":"2024-11-29","current":-8.390781,"twenty":-21.853523,"median":-19.866839,"eighty":-18.304981,"marketCap":136412089},{"date":"2024-12-06","current":-4.81693,"twenty":-21.258393,"median":-18.273744,"eighty":-7.899765,"marketCap":78310643},{"date":"2024-12-13","current":-4.972315,"twenty":-20.411365,"median":-8.390781,"eighty":-5.307946,"marketCap":80836793},{"date":"2024-12-20","current":-4.630468,"twenty":-19.585704,"median":-7.054472,"eighty":-4.754776,"marketCap":75279264},{"date":"2024-12-27","current":-9.354167,"twenty":-19.01094,"median":-7.505088,"eighty":-4.779638,"marketCap":152074217},{"date":"2025-01-03","current":-4.879084,"twenty":-18.367455,"median":-7.054472,"eighty":-4.829361,"marketCap":79321103},{"date":"2025-01-10","current":-4.008929,"twenty":-18.117558,"median":-6.526163,"eighty":-4.754776,"marketCap":65174664},{"date":"2025-01-17","current":-4.195391,"twenty":-13.953559,"median":-5.562777,"eighty":-4.242006,"marketCap":68206044},{"date":"2025-01-24","current":-8.381212,"twenty":-10.274045,"median":-5.5317,"eighty":-4.189176,"marketCap":64669434},{"date":"2025-01-31","current":-6.744257,"twenty":-8.628186,"median":-6.060009,"eighty":-4.195391,"marketCap":52038685},{"date":"2025-02-07","current":-7.00617,"twenty":-8.401963,"median":-6.285909,"eighty":-4.232683,"marketCap":54059605},{"date":"2025-02-14","current":-6.6133,"twenty":-8.390781,"median":-6.457638,"eighty":-4.503052,"marketCap":51028225},{"date":"2025-02-21","current":-6.154953,"twenty":-8.38504,"median":-6.460736,"eighty":-4.568314,"marketCap":47491616},{"date":"2025-02-28","current":-3.797737,"twenty":-8.263352,"median":-6.416866,"eighty":-4.434578,"marketCap":29303337},{"date":"2025-03-07","current":-3.478858,"twenty":-8.177857,"median":-6.257426,"eighty":-4.18296,"marketCap":26842867},{"date":"2025-03-14","current":-3.080096,"twenty":-7.787294,"median":-5.687085,"eighty":-4.028744,"marketCap":23766017},{"date":"2025-03-21","current":-3.000867,"twenty":-7.524374,"median":-5.506113,"eighty":-3.915698,"marketCap":23154689},{"date":"2025-03-28","current":-2.695084,"twenty":-7.520626,"median":-4.979619,"eighty":-3.467596,"marketCap":20795265},{"date":"2025-04-04","current":-2.363764,"twenty":-7.50198,"median":-4.894623,"eighty":-3.339389,"marketCap":18238801},{"date":"2025-04-11","current":-1.71422,"twenty":-7.395956,"median":-4.754776,"eighty":-3.180932,"marketCap":13226920},{"date":"2025-04-17","current":-1.742819,"twenty":-7.202605,"median":-4.630468,"eighty":-3.128942,"marketCap":12604067},{"date":"2025-04-25","current":-2.345012,"twenty":-7.00617,"median":-4.528423,"eighty":-2.892566,"marketCap":16959130},{"date":"2025-05-02","current":-1.551534,"twenty":-6.927596,"median":-4.242006,"eighty":-2.702941,"marketCap":11220693},{"date":"2025-05-09","current":-1.374418,"twenty":-6.783544,"median":-4.179852,"eighty":-2.352513,"marketCap":9939792},{"date":"2025-05-16","current":-1.878135,"twenty":-6.694312,"median":-4.040006,"eighty":-2.089541,"marketCap":13582675},{"date":"2025-05-23","current":-1.041496,"twenty":-6.619394,"median":-4.01039,"eighty":-1.859432,"marketCap":11905342},{"date":"2025-05-30","current":-1.204886,"twenty":-6.618175,"median":-3.977852,"eighty":-1.811326,"marketCap":14163434},{"date":"2025-06-06","current":-1.097842,"twenty":-6.6133,"median":-3.797737,"eighty":-1.715791,"marketCap":12905137},{"date":"2025-06-13","current":-1.196095,"twenty":-6.589728,"median":-3.46478,"eighty":-1.630882,"marketCap":14060096},{"date":"2025-06-20","current":-1.080777,"twenty":-6.49544,"median":-3.411666,"eighty":-1.551534,"marketCap":12704539},{"date":"2025-06-27","current":-1.153174,"twenty":-6.482344,"median":-3.339389,"eighty":-1.416926,"marketCap":13555561},{"date":"2025-07-03","current":-0.972183,"twenty":-6.482344,"median":-3.198611,"eighty":-1.323927,"marketCap":11428007},{"date":"2025-07-11","current":-1.00683,"twenty":-6.447771,"median":-3.167836,"eighty":-1.217296,"marketCap":11835281},{"date":"2025-07-18","current":-1.014586,"twenty":-6.434171,"median":-3.123966,"eighty":-1.154034,"marketCap":11926462},{"date":"2025-07-25","current":-1.376052,"twenty":-6.420079,"median":-2.994646,"eighty":-1.153174,"marketCap":16175493},{"date":"2025-08-01","current":-1.336234,"twenty":-6.3121,"median":-2.818837,"eighty":-1.154034,"marketCap":15707431},{"date":"2025-08-08","current":-1.238499,"twenty":-6.285909,"median":-2.704251,"eighty":-1.166021,"marketCap":14558551},{"date":"2025-08-15","current":-1.639965,"twenty":-6.240336,"median":-2.685262,"eighty":-1.173707,"marketCap":20169933},{"date":"2025-08-22","current":-1.590427,"twenty":-6.169751,"median":-2.320925,"eighty":-1.191855,"marketCap":19560666},{"date":"2025-08-29","current":-1.588472,"twenty":-5.780659,"median":-2.226259,"eighty":-1.203128,"marketCap":19536616},{"date":"2025-09-05","current":-1.596946,"twenty":-5.6125,"median":-1.931607,"eighty":-1.214194,"marketCap":19640833},{"date":"2025-09-12","current":-1.061154,"twenty":-5.544131,"median":-1.862549,"eighty":-1.187614,"marketCap":13051133},{"date":"2025-09-19","current":-1.303629,"twenty":-5.500996,"median":-1.827834,"eighty":-1.181348,"marketCap":16033333},{"date":"2025-09-26","current":-1.39032,"twenty":-5.194246,"median":-1.77831,"eighty":-1.186042,"marketCap":17099550},{"date":"2025-10-03","current":-1.488744,"twenty":-4.989128,"median":-1.733827,"eighty":-1.192178,"marketCap":18310066},{"date":"2025-10-10","current":-1.287334,"twenty":-4.975237,"median":-1.708327,"eighty":-1.20137,"marketCap":15832916},{"date":"2025-10-17","current":-1.225411,"twenty":-4.935023,"median":-1.674511,"eighty":-1.199339,"marketCap":15071333},{"date":"2025-10-24","current":-1.304281,"twenty":-4.891515,"median":-1.660419,"eighty":-1.202667,"marketCap":16041350},{"date":"2025-10-31","current":-1.277556,"twenty":-4.841792,"median":-1.639965,"eighty":-1.214194,"marketCap":15712666},{"date":"2025-11-07","current":-1.217697,"twenty":-4.779638,"median":-1.630228,"eighty":-1.199339,"marketCap":14976457},{"date":"2025-11-14","current":-1.276251,"twenty":-4.754776,"median":-1.62238,"eighty":-1.201896,"marketCap":15696607},{"date":"2025-11-21","current":-1.432202,"twenty":-4.680191,"median":-1.603789,"eighty":-1.201896,"marketCap":16990210},{"date":"2025-11-28","current":-1.557,"twenty":-4.605606,"median":-1.597597,"eighty":-1.204115,"marketCap":18470690},{"date":"2025-12-05","current":-1.458543,"twenty":-4.568314,"median":-1.596946,"eighty":-1.21001,"marketCap":17302690},{"date":"2025-12-12","current":-1.357795,"twenty":-4.536401,"median":-1.58945,"eighty":-1.218131,"marketCap":16107528},{"date":"2025-12-19","current":-1.096769,"twenty":-4.434578,"median":-1.579998,"eighty":-1.204115,"marketCap":13010971},{"date":"2025-12-26","current":-1.083031,"twenty":-4.331319,"median":-1.565703,"eighty":-1.196744,"marketCap":12847994},{"date":"2026-01-02","current":-0.968545,"twenty":-4.242006,"median":-1.557,"eighty":-1.186302,"marketCap":11489855},{"date":"2026-01-09","current":-0.929621,"twenty":-4.195391,"median":-1.545517,"eighty":-1.160882,"marketCap":11028088},{"date":"2026-01-13","current":-0.897565,"twenty":-4.195391,"median":-1.54141,"eighty":-1.156971,"marketCap":10647809}],"updateTime":1768384610716},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABP\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1193338956","title":"Abpro與Celltrion達成全球合作 臨牀試驗預計2026年上半年啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=1193338956","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193338956?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700881,"startTime":"0","endTime":"0","summary":"ABPRO HLDGS INC近日宣布，通过与韩国生物制药企业Celltrion的全球战略合作，其创新药物临床试验计划预计将于2026年上半年正式启动。此次合作将整合Abpro在抗体疗法领域的技术优势与Celltrion的规模化生产实力，共同推进肿瘤治疗领域的研发进程。根据双方协议，Abpro将负责前期研发及临床方案设计，Celltrion则承担临床阶段的生产供应与全球商业化支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"1133031799","title":"Abpro與Celltrion宣佈其領先多特異性抗體抗癌候選藥物Abp-102/Ct-P72獲美國FDA IND許可","url":"https://stock-news.laohu8.com/highlight/detail?id=1133031799","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133031799?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 20:01","pubTimestamp":1767700876,"startTime":"0","endTime":"0","summary":"Abpro公司与Celltrion公司联合宣布，其核心多特异性抗体抗癌候选药物Abp-102（亦称为Ct-P72）已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）批准。\n这一重要进展标志着该创新疗法正式获准进入临床开发阶段，为后续的人体试验铺平道路。Abp-102/Ct-P72作为一种多特异性抗体，旨在通过靶向多个癌症信号通路，更有效地攻击肿瘤细胞。\n此次IND获批是基于临床前研究显示的积极数据，证明了其在治疗特定癌症类型方面的潜力。两家公司计划迅速推进临床试验，以评估该药物在患者中的安全性和有效性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0},{"id":"2601483161","title":"Abpro Holdings, Inc盤中異動 早盤股價大跌5.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601483161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601483161?lang=zh_tw&edition=fundamental","pubTime":"2026-01-06 00:17","pubTimestamp":1767629820,"startTime":"0","endTime":"0","summary":"北京时间2026年01月06日00时17分，Abpro Holdings, Inc股票出现波动，股价急速下挫5.69%。Abpro Holdings, Inc股票所在的生物技术行业中，整体跌幅为1.80%。Abpro Holdings, Inc公司简介：Abpro Holdings Inc 是一家致力于开发下一代抗体疗法的生物技术公司，其目标是改善患有严重和危及生命疾病的患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106001700953c05cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260106001700953c05cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ABP"],"gpt_icon":0},{"id":"1137956025","title":"ABPRO HLDGS INC提交IND申請以啓動Abp-102/Ct-P72針對HER2陽性癌症的I期臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=1137956025","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137956025?lang=zh_tw&edition=fundamental","pubTime":"2025-12-15 20:02","pubTimestamp":1765800144,"startTime":"0","endTime":"0","summary":"ABPRO HLDGS INC提交IND申请以启动Abp-102/Ct-P72针对HER2阳性癌症的I期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABP"],"gpt_icon":0},{"id":"1141509871","title":"ABPRO控股公司提交有關可發行和轉售高達978萬股普通股的招股説明書 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1141509871","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141509871?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 01:08","pubTimestamp":1763572117,"startTime":"0","endTime":"0","summary":"11月7日 - ABPRO控股公司宣布，已向美国证券交易委员会（SEC）提交招股说明书，内容涉及可发行和转售高达978万股普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABP"],"gpt_icon":0},{"id":"1105117866","title":"ABPRO HLDGS INC：提交關於提供和轉售高達978萬股普通股的招股説明書 - SEC備案","url":"https://stock-news.laohu8.com/highlight/detail?id=1105117866","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105117866?lang=zh_tw&edition=fundamental","pubTime":"2025-11-07 20:45","pubTimestamp":1762519515,"startTime":"0","endTime":"0","summary":"ABPRO HLDGS INC：提交关于提供和转售高达978万股普通股的招股说明书 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABP","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}